Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say

Glaukos (GKOS) reported $185.61 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 49.5%. EPS of -$0.14 for the same period compares to -$0.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $149.57 million, representing a surprise of +24.1%. The company delivered an EPS surprise of +50%, with the consensus EPS estimate being -$0.28.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues by geography- United States: $146.74 million compared to the $112.26 million average estimate based on four analysts. The reported number represents a change of +62.1% year over year.
• Revenues by product category- United States- Glaucoma: $118.5 million versus $96.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +63.9% change.
• Revenues by product category- International- Corneal Health: $2.24 million compared to the $2.64 million average estimate based on four analysts. The reported number represents a change of -4.7% year over year.
• Revenues by geography- International: $38.87 million versus the four-analyst average estimate of $37.05 million. The reported number represents a year-over-year change of +15.7%.
• Revenues by product category- International- Glaucoma: $36.63 million versus $34.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +17.2% change.
• Revenues by product category- United States- Corneal Health: $28.19 million versus the four-analyst average estimate of $15.98 million. The reported number represents a year-over-year change of +54.6%.
• Net Sales- Corneal Health: $30.43 million compared to the $19.2 million average estimate based on five analysts. The reported number represents a change of +47.8% year over year.
• Net Sales- Glaucoma: $155.2 million compared to the $130.55 million average estimate based on five analysts. The reported number represents a change of +49.9% year over year.

View all Key Company Metrics for Glaukos here>>>

Shares of Glaukos have returned +8.3% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research